GeNeuro SA (GEM.F)
| Previous Close | 1.3250 |
| Open | 1.3250 |
| Bid | 1.3350 x 40000 |
| Ask | 1.5400 x 40000 |
| Day's Range | 1.3250 - 1.3250 |
| 52 Week Range | 0.8540 - 1.9750 |
| Volume | |
| Avg. Volume | 31 |
| Market Cap | 42.323M |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireGeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting
GENEVA, March 20, 2024--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024. These included among o
Business WireGeNeuro Announces a Successful €5 Million Private Placement
GENEVA, Switzerland, February 02, 2024--Regulatory News: NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO
Business WireGeNeuro Launches an Offering With a Commitment to Subscribe by Existing Shareholders and Announces Its Cash Position at December 31, 2023
GENEVA, Switzerland, February 01, 2024--Regulatory News: NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO
